Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,128 public posts
Filter results
Androgen Receptor Pathway-Independent PCa.
Castration
or DES treatment mostly fails within 18 to 24 months, but with late diagnosis & high male mortality rates from other causes, compared to today, Huggins must have seemed like a hero. {In 1950, The PCa mortality rate in the U.S. was 28.6 per 100,000 lives.
Castration
or DES treatment mostly fails within 18 to 24 months, but with late diagnosis & high male mortality rates from other causes, compared to today, Huggins must have seemed like a hero. {In 1950, The PCa mortality rate in the U.S. was 28.6 per 100,000 lives.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Apalutamide + ADT Improves Survival in crPCa
https://prostatecancernewstoday.com/2017/10/13/janssen-submits-new-drug-application-to-u-s-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-
castration
-resistant-prostate-cancer/?
https://prostatecancernewstoday.com/2017/10/13/janssen-submits-new-drug-application-to-u-s-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-
castration
-resistant-prostate-cancer/?
gusgold
in
Advanced Prostate Cancer
7 years ago
DHEA & ADT
Contrary to the previous belief that the testes are responsible for 90–95% of total androgen production in men (as could be inferred from the 90–95% decrease in serum testosterone observed after
castration
), it is now well demonstrated that the prostatic tissue efficiently transforms the inactive steroid
Contrary to the previous belief that the testes are responsible for 90–95% of total androgen production in men (as could be inferred from the 90–95% decrease in serum testosterone observed after
castration
), it is now well demonstrated that the prostatic tissue efficiently transforms the inactive steroid
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Hadi1954
I had my normal life and activity in spite of little tiredness.but it seems that
castration
resistance is performed and my Oncologist now thinking about add Casodex to my treatment plan. I appreciate to get advises from any of this community to fight with this brutal disease and win.
I had my normal life and activity in spite of little tiredness.but it seems that
castration
resistance is performed and my Oncologist now thinking about add Casodex to my treatment plan. I appreciate to get advises from any of this community to fight with this brutal disease and win.
Hadi1954
in
Advanced Prostate Cancer
7 years ago
Enzalutamide & Management of Anticoagulation.
Author information Abstract Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic,
castration
-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events
Author information Abstract Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic,
castration
-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Apalutamide (ARN-509) & the SPARTAN Trial.
"Studies have estimated that between 10 and 20 percent of patients diagnosed with prostate cancer might develop the
castration
-resistant form within about five years.
"Studies have estimated that between 10 and 20 percent of patients diagnosed with prostate cancer might develop the
castration
-resistant form within about five years.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
ADT + Xtandi Will Soon Be Standard of Care
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/99108-prosper-trial-results-of-enzalutamide-in-non-metastatic-
castration
-resistant-prostate-cancer.html Gus
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/99108-prosper-trial-results-of-enzalutamide-in-non-metastatic-
castration
-resistant-prostate-cancer.html Gus
gusgold
in
Advanced Prostate Cancer
7 years ago
Update on 8th round of chemo
Search for this article: "Determine of the optimal number of cycles of docetaxel in the treatment of metastatic
castration
-resistant prostate cancer"; published in The Kaohsiung Journal of Medical Sciences Sep 2016 issue.
Search for this article: "Determine of the optimal number of cycles of docetaxel in the treatment of metastatic
castration
-resistant prostate cancer"; published in The Kaohsiung Journal of Medical Sciences Sep 2016 issue.
bb66hotflash
in
Advanced Prostate Cancer
7 years ago
Which form of abiraterone?
[Epub ahead of print] Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic
castration
-resistant prostate cancer: The STAAR study.
[Epub ahead of print] Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic
castration
-resistant prostate cancer: The STAAR study.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Lynparza (olaparib), a PARP inhibitor, before CRPC.
Some hype over a new study [1]: "Our data suggest that ADT can functionally impair HR {defects} prior to the development of
castration
resistance and that, this potentially could be exploited therapeutically using PARP inhibitors in combination with androgen-deprivation therapy upfront in advanced or
Some hype over a new study [1]: "Our data suggest that ADT can functionally impair HR {defects} prior to the development of
castration
resistance and that, this potentially could be exploited therapeutically using PARP inhibitors in combination with androgen-deprivation therapy upfront in advanced or
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Tasquinimod
Based on these encouraging phase II results, a randomized, double-blind, placebo-controlled trial in men with metastatic
castration
-resistant PCa was launched. That trial is powered for a primary endpoint of progression-free survival and is expected to enroll 1200 men."
Based on these encouraging phase II results, a randomized, double-blind, placebo-controlled trial in men with metastatic
castration
-resistant PCa was launched. That trial is powered for a primary endpoint of progression-free survival and is expected to enroll 1200 men."
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Enzalutamide & drug interactions.
Abstract AIM: Metastatic
castration
resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore more at risk for complications due to drug-drug interactions(DDIs).
Abstract AIM: Metastatic
castration
resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore more at risk for complications due to drug-drug interactions(DDIs).
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Re-treatment with radium-223.
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with
castration
-resistant prostate cancer and bone metastases.
Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with
castration
-resistant prostate cancer and bone metastases.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
May be of interest to some
GUID=18456D86-A23E-480C-A0A9-98C406D1C617&XGUID=&rememberme=1&ts=07092017 http://www.cancernetwork.com/prostate-cancer/management-
castration
-resistant-taxane-resistant-prostate-cancer?
GUID=18456D86-A23E-480C-A0A9-98C406D1C617&XGUID=&rememberme=1&ts=07092017 http://www.cancernetwork.com/prostate-cancer/management-
castration
-resistant-taxane-resistant-prostate-cancer?
Hidden
in
Advanced Prostate Cancer
7 years ago
Another 'Time to PSA Nadir' [TTN] study.
[Epub ahead of print] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in
castration
-resistant prostate cancer: evidence from patients in Northwestern China. Wu KJ1, Pei XQ1, Tian G1, Wu DP1, Fan JH1, Jiang YM1, He DL1.
[Epub ahead of print] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in
castration
-resistant prostate cancer: evidence from patients in Northwestern China. Wu KJ1, Pei XQ1, Tian G1, Wu DP1, Fan JH1, Jiang YM1, He DL1.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Metastatic prostate cancer of bone and bone marrow
I have had prostate cancer for 8 years...Had surgery(can't think of name for it but it's like
castration
About 6 years ago) tried casadex and Lupron but I was allergic to both. I am a very active 92 years old.
I have had prostate cancer for 8 years...Had surgery(can't think of name for it but it's like
castration
About 6 years ago) tried casadex and Lupron but I was allergic to both. I am a very active 92 years old.
sidnw
in
Advanced Prostate Cancer
7 years ago
Rapidly decreasing level of PSA during ADT is a risk factor for early progression to CRPC.
Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to
castration
-resistant prostate cancer: A retrospective study. Ji G1, Song G, Huang C, He S, Zhou L.
Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to
castration
-resistant prostate cancer: A retrospective study. Ji G1, Song G, Huang C, He S, Zhou L.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
HIF-1α inhibition by DES.
Median TDP {time to disease progression} was 20.4 months for LH-RH analog treatment in the
castration
-sensitive phase, and 7.1 months for DES treatment in the
castration
-resistant phase. Durable responses (>1 year) were observed in 31% of the patients.
Median TDP {time to disease progression} was 20.4 months for LH-RH analog treatment in the
castration
-sensitive phase, and 7.1 months for DES treatment in the
castration
-resistant phase. Durable responses (>1 year) were observed in 31% of the patients.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Quercetin & AR-V7.
Abstract Prostate cancer remains dependent on androgen receptor signaling even after
castration
. Aberrant androgen receptor signaling in
castration
resistant prostate cancer is mediated by mechanisms such as alterations in the androgen receptor and activation of interacting signaling pathways.
Abstract Prostate cancer remains dependent on androgen receptor signaling even after
castration
. Aberrant androgen receptor signaling in
castration
resistant prostate cancer is mediated by mechanisms such as alterations in the androgen receptor and activation of interacting signaling pathways.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Morgentaler & Testosterone Flare
Rates of spinal cord compression were no greater for LHRH agonists alone compared with
castration
or estrogen treatment. We identified no studies of men treated with LHRH agonists versus placebo/no treatment to assess the effects of LHRH agonists compared with the natural history of advanced PCa.
Rates of spinal cord compression were no greater for LHRH agonists alone compared with
castration
or estrogen treatment. We identified no studies of men treated with LHRH agonists versus placebo/no treatment to assess the effects of LHRH agonists compared with the natural history of advanced PCa.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
1
...
51
52
53
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1005 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest